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Objectives The aim of this study was to examine the use of and outcomes associated with use of
N-acetylcysteine (NAC) in real-world practice.
Background The role of NAC in the prevention of contrast-induced nephropathy (CIN) is controver-
sial, leading to widely varying recommendations for its use.
Methods Use of NAC was assessed in consecutive patients undergoing nonemergent percutaneous
coronary intervention from 2006 to 2009 in the Blue Cross Blue Shield of Michigan Cardiovascular
Consortium, a large multicenter quality improvement collaborative. We examined the overall preva-
lence of NAC use in these patients and then used propensity matching to link its use with clinical
outcomes, including CIN, nephropathy-requiring dialysis, and death.
Results Of the 90,578 percutaneous coronary interventions performed during the study period,
NAC was used in 10,574 (11.6%) procedures, with its use steadily increasing over the study period.
Patients treated with NAC were slightly older and more likely to have baseline renal insufﬁciency
and other comorbidities. In propensity-matched, risk-adjusted models, we found no differences in
outcomes between patients treated with NAC and those not receiving NAC for CIN (5.5% vs. 5.5%,
p  0.99), nephropathy-requiring dialysis (0.6% vs. 0.6%, p  0.69), or death (0.6% vs. 0.8%,
p  0.15). These ﬁndings were consistent across many prespeciﬁed subgroups.
Conclusions Use of NAC is common and has steadily increased over the study period but does not
seem to be associated with improved clinical outcomes in real-world practice. (J Am Coll Cardiol
Intv 2012;5:98–104) © 2012 by the American College of Cardiology Foundation
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99Contrast-induced nephropathy (CIN) is a common com-
plication of percutaneous coronary intervention (PCI) and
responsible for excessive morbidity, mortality, and health-
care cost (1–5). Multiple strategies have been explored to
reduce the occurrence of CIN after PCI (6), although the
only proven strategies remain adequate peri-procedural
hydration, avoidance of hyperosmolar contrast media, and
minimization of contrast volume (7,8).
On the basis of the assumption that free radicals play a
role in mediating CIN, a number of antioxidant agents have
been studied in recent years with mixed results (9). The
most notable of these is N-acetylcysteine (NAC), whose use
as first described a decade ago (10). Yet multiple random-
zed clinical trials have demonstrated conflicting results
bout its clinical benefits, which has led to varying recom-
endations for its use (11). The recently presented and
arge ACT (Acetylcysteine for the prevention of Contrast-
nduced nephropathy Trial) demonstrated no apparent ben-
fit for NAC with respect to occurrence of CIN (12).
lthough the ACT trial provided important data in this
ebate, even this large study is limited in its ability to
xamine high-risk patient subgroups, such as those receiving
arge doses of contrast, or “hard” clinical outcomes like
ephropathy-requiring dialysis or death.
As such, there remains a paucity of data on the overall
ptake of NAC in real-world practice and its association
ith outcomes. The aims of our study were 2-fold. First, we
sought to identify the prevalence of NAC use in a broad and
unselected population of patients undergoing PCI in the
BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular
Consortium) a large multicenter quality improvement collab-
orative. Second, we assessed the impact of NAC use on
reducing CIN, dialysis, and death, focusing on patient sub-
groups that might be at particularly high risk for these
complications but in whom data are more sparse.
Methods
Data sources and study population. We included data from
31 hospitals in the BMC2. The details of the BMC2 and its
data collection and auditing process have been described
previously (13–15). Briefly, procedural data on all patients
undergoing PCI at participating hospitals are collected with
standardized data collection forms. Baseline data include
clinical, demographic, procedural, and angiographic charac-
teristics as well as medications used before, during, and after
the procedure and in-hospital outcomes. All data elements
have been prospectively defined, and the protocol is ap-
proved by local institutional review boards at each hospital.
In addition to a random audit of 2% of all cases, medical
records of all patients undergoing multiple procedures or
coronary artery bypass grafting and of patients who died in
the hospital are reviewed routinely to ensure data accuracy.The study population for this analysis included all con-
secutive patients who underwent nonemergent PCI between
January 1, 2006, and December 31, 2009. We excluded
patients undergoing PCI for ST-segment elevation myocar-
dial infarction, cardiogenic shock, or cardiac arrest, because
the urgency inherent in performing PCI for these indica-
tions precludes administration of oral NAC. We also
excluded patients who were already receiving dialysis at the
time of their procedure or those who died in the catheter-
ization laboratory because they did not survive long enough
to possibly benefit from NAC. N-acetylcysteine use was
defined as administration of at least 1 oral dose of NAC
within the 24 h before the procedure. The dose and
duration of NAC administration was as per the local
institutional protocol and operator preference.
Study endpoints. Our study had 3 endpoints for this anal-
sis: CIN, nephropathy-requiring dialysis, and in-hospital
eath. The CIN was defined as impairment in renal function
esulting in 0.5 mg/dl absolute increase in serum creatinine
rom baseline. Baseline creatinine was collected within 1
onth of the procedure. Among patients who had multiple
ssessments of serum creatinine in
he 30 days before the procedure,
he value closest to the time of the
rocedure was considered as the
aseline value. Peak creatinine
as defined as the highest value of
reatinine in the week after the
rocedure and was ascertained as
er local clinical practice. A
ollow-up creatinine was collected
t least 1 day after the procedure
ut varied, depending on length of
tay. Nephropathy-requiring dialysis was defined as new, un-
lanned need for hemodialysis during the hospital stay for
atients, due to worsening of renal function after PCI. In-
ospital death was obtained from the medical records.
Statistical analysis. We separated patients into 2 categories:
those treated with NAC pre-procedurally, and those who were
not. Continuous variables were expressed as mean  SD, and
discrete variables were expressed as frequency counts and
percentages. Continuous variables were analyzed with the
Student t test, with the Wilcoxon rank-sum test used for
skewed variables. Differences in discrete variables between
patients treated with NAC and those who did not receive it
were evaluated by the chi-square-test and Fisher exact test. Trends
in NAC use over time in all patients and in different patient
subgroups were assessed with the Cochran Armitage test.
We used propensity matching to account for the nonran-
dom use of NAC (16,17). A propensity score for receiving
NAC was calculated with a nonparsimonious logistic re-
gression model created from several pre-procedural patient
characteristics. These patient characteristics included age,
Abbreviations
and Acronyms
CIN  contrast-induced
nephropathy
GFR  glomerular filtration
rate
NAC  N-acetylcysteine
PCI  percutaneous
coronary interventionsex, baseline glomerular filtration rate (GFR), smoking
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100status, history of hypertension, diabetes, prior myocardial
infarction, congestive heart failure, prior coronary revascu-
larization (PCI or coronary artery bypass grafting), atrial
fibrillation, peripheral vascular disease, history of stroke or
transient ischemic attack, and chronic obstructive pulmo-
nary disease. Greedy matching technique was then used to
match a patient receiving NAC to a patient with the nearest
propensity score who did not receive NAC to permit
adequate comparison of similar patients (18). Matching
adequacy was confirmed by calculating the standardized
differences for baseline variables among the matched subset,
with a standardized difference of10% suggesting adequate
matching. The study endpoints were then compared within
this propensity-matched cohort. Random effect hierarchical
models were fitted to control for clustering and variation by
hospital. Separate models were developed for CIN,
nephropathy-requiring dialysis, and in-hospital death.
We further evaluated differences in outcomes among
several key, high-risk patient subgroups with each subgroup
defined by the presence or absence of a single high-risk
characteristic. These subgroups included patients with ab-
normal renal function at baseline, diabetes, and anemia and
those treated with high contrast volume and by the specific
type of contrast media employed (iso-osmolar contrast or
low osmolar contrast media). Glomerular filtration rate was
estimated with the Modification of Diet in Renal Disease
equation (19). Adjustment for multiple comparisons was
performed during these additional analyses with the false
discovery rate method (20). The SAS software (version 9.1,
SAS, Cary, North Carolina) was used for all analysis.
Results
Our study population comprised 90,578 PCI procedures with
NAC used in 10,574 (11.64%) patients. A slight increase in
the proportion of patients treated with NAC was noted over
time, increasing from 10.1% to 13.0% over the study period.
Use of NAC was common in patients with abnormal renal
function at baseline, including 58.6% of patients with a serum
creatinine 1.5 mg/dl and 68.7% of those with a serum
reatinine2 mg/dl. Baseline characteristics of patients treated
ith NAC compared with those not receiving NAC are
escribed in Table 1. Patients treated with NAC were older,
ore likely to have worse renal function at baseline, and had
ore comorbidities, including hypertension, diabetes, anemia,
ower ejection fraction, prior coronary artery disease, and prior
oronary revascularization. The average dose of contrast media
sed was slightly lower in patients treated with NAC, although
rocedure duration as assessed by total fluoroscopic time was
onger. Significant variation in NAC use was noted across the
ifferent hospitals, ranging from 1.4% to 33.0% of all treated
atients.
By comparison, the propensity-matched cohorts wereell-balanced, with no major difference in the baseline gharacteristics of patients treated with NAC compared with
hose not receiving NAC (Table 2). The model developed
o predict the propensity score had a C statistic of 0.86,
uggesting high discrimination. Overall, unadjusted and
djusted outcomes for the study cohort are described in
able 3. In unadjusted analyses, patients treated with NAC
ad a significantly higher incidence of CIN, nephropathy-
equiring dialysis, and in-hospital death. However, no
ifferences in the incidence of CIN, nephropathy-requiring
ialysis, and in-hospital death were observed between
atients treated with NAC compared with those who did
ot receive it in the propensity-matched analysis (Fig. 1,
able 3). When we examined the occurrence of CIN and
ephropathy-requiring dialysis in different patient sub-
roups, a lower incidence of CIN was noted in patients with
FR 30 ml/min/1.73 m2, but this was not significant
fter adjusting for multiple comparisons (Fig. 2A). No
ifference in outcomes was observed in any other sub-
Table 1. Baseline Characteristics of Patients by Pre-Procedural Use
of NAC
Pre-Procedural
NAC Use
(n  10,547)
No Pre-Procedural
NAC
(n  80,031) p Value
Age, yrs 70.8 11.0 64.5 11.8 0.0001
Age 60–69 yrs 25.4 30.2 0.0001
Age 70–79 yrs 33.6 23.9 0.0001
Age 80 yrs 24.4 11.2 0.0001
Female 36.8 34.7 0.0001
Current smoking 15.5 24.1 0.0001
GFR 60–89 19.6 43.7 0.0001
GFR 30–59 62.7 22.6 0.0001
GFR 30 12.2 0.9 0.0001
History of hypertension 94.5 85.6 0.0001
Prior MI 45.2 36.3 0.0001
Diabetes mellitus 55.8 34.8 0.0001
Congestive heart failure 35.2 14.0 0.0001
Peripheral vascular disease 44.5 25.9 0.0001
Signiﬁcant valve disease 7.8 3.9 0.0001
Gastrointestinal bleeding 3.1 1.5 0.0001
Atrial ﬁbrillation 18.5 9.6 0.0001
Prior cardiac arrest 1.4 1.1 0.04
Prior PCI 52.5 49.0 0.0001
Prior CABG 31.3 20.4 0.0001
COPD 26.7 18.8 0.0001
MI within the last 7 days 20.7 13.8 0.0001
Anemia 55.1 25.6 0.0001
Ejection fraction 49.0 13.2 53.2 11.1 0.0001
Total contrast, ml 188 87 207 84 0.0001
Total ﬂuoroscopy time, min 15.7 11.6 14.6 11.5 0.0001
Values are mean  SD or %. Glomerular filtration rate (GFR) is an estimated value and was
calculated with the Modification of Diet in Renal Disease equation (19).
CABG coronary artery bypass grafting; COPD chronic obstructive pulmonary disease;MI
myocardial infarction; NAC N-acetylcysteine; PCI percutaneous coronary intervention.roup on the basis of baseline renal function, presence or
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101absence of diabetes or anemia, the contrast dose, or the
specific type of contrast media employed (iso-osmolar
contrast or low osmolar contrast media) (Fig. 2). Simi-
larly, when patients were categorized as those with a
baseline serum creatinine 1.5 mg/dl or 1.5 mg/dl, no
difference in the incidence of CIN (4.32% vs. 3.98%, p 
0.41, among those with serum creatinine 1.5 mg/dl; and
7.14% vs. 7.76%, p 0.35, among those with serum creatinine
1.5 mg/dl) or nephropathy-requiring dialysis (0.17% vs.
0.13%, p  0.57, among those with serum creatinine 1.5
g/dl; and 1.29% vs. 1.29%, p  0.99, among those with
erum creatinine 1.5 mg/dl) was observed among patients
reated with NAC compared with the matched set of patients
ho were not treated with NAC.
Table 2. Baseline Characteristics of the Propensity-Matched Cohort
Pre-Procedural
NAC
(n  8,626)
No Pre-Procedural
NAC
(n  8,626)
% Standardized
Difference
Age 60–69 yrs 25.5 25.1 0.92
Age 70–79 yrs 33.5 35.7 4.62
Age 80 yrs 23.7 23.6 0.23
Female 37.0 37.9 1.85
Current smoking 15.7 15.6 0.27
GFR 60–89 23.2 22.8 0.95
GFR 30–59 62.2 64.6 4.98
GFR 30 8.0 7.2 3.01
Hypertension 93.9 93.2 2.84
Prior MI 43.5 44.4 1.81
Diabetes mellitus 52.6 52.7 0.20
Congestive heart failure 31.1 31.7 1.29
Peripheral vascular disease 41.6 42.5 1.82
Signiﬁcant valve disease 7.1 7.4 1.15
Gastrointestinal bleeding 2.8 2.8 0
Atrial ﬁbrillation 17.2 17.8 1.57
History of cardiac arrest 1.3 1.5 1.70
Prior PCI 51.6 51.8 0.40
Prior CABG 29.6 30.1 1.09
COPD 24.8 26.2 3.21
Values are %. Baseline characteristics of the propensity-matched cohort comparing those who
received NAC with a matched group of patients who were not treated with NAC. The GFR is an
estimated value and was calculated with the Modification of Diet in Renal Disease equation (19).
All standardized difference are10%, suggesting adequate matching.
Abbreviations as in Table 1.
Table 3. Unadjusted and Propensity-Matched In-Hospital Outcome of Patie
Unadjusted Outcome
Pre-Procedural NAC
(n  10,547)
No Pre-Procedural N
(n  80,031)
CIN 663 (6.87) 1,158 (1.31)
Nephropathy-requiring dialysis 103 (0.98) 74 (0.09)
Death 81 (0.77) 213 (0.27)
Values are n (%). Unadjusted and propensity-matched in-hospital outcome of patients treated withCIN contrast-induced nephropathy.In a sensitivity analysis, no difference in the incidence of
IN or nephropathy-requiring dialysis was noted among
he propensity-matched cohort in patients with a post-
rocedural length of stay of 2 days (n  2,180, CIN 3.23%
ith NAC vs. 4.42%, p  0.15, and nephropathy-requiring
ialysis 0.17% vs. 0.30%, p  0.53) or among those with a
ength of stay of 3 days or longer (n  3,383, CIN 20.54%
ith NAC vs. 20.70%, p  0.91, and nephropathy-
equiring dialysis 2.95% vs. 2.66%, p  0.60).
iscussion
The key finding of our study is that, in our study population,
NAC is commonly used in patients undergoing PCI,
although it seems to have no consistently beneficial effects
on in-hospital outcomes. The results of our study add to and
extend the findings of the recently presented ACT trial in 2
important ways. First, the large size of our study cohort
allowed us to examine the impact of NAC on hard out-
comes, such as nephropathy-requiring dialysis and death.
Second, we were able to assess outcomes among subgroups,
such as those with advanced renal dysfunction or those
treated with large volumes of contrast media that were
under-represented in the ACT trial.
Importantly, in these additional subgroup analyses, we
identified a possible reduction in CIN in patients with a
GFR 30 ml/min/1.73 m2, although there was no reduc-
tion in nephropathy-requiring dialysis. A possible explana-
tion is that this simply reflects a chance finding, because
there was no trend for significance after adjusting for
multiple comparisons. Given the consistently null results
observed in our study, it is unlikely that NAC has any
clinically relevant effect in patients undergoing PCI, but this
isolated group might be worthy of further study. Until
additional studies are performed, however, we would not
recommend its use on the basis of this isolated result.
The widespread use of NAC especially in patients with
abnormal renal function despite the lack of definitive evidence
is noteworthy. The evidence base supporting NAC is incon-
sistent, yet some authorities advocate its use on the assumption
of low cost, possible benefit, and lack of harm (21). Although
a few trials and meta-analysis have demonstrated dramatic
Propensity-Matched Outcome
p Value
Pre-Procedural NAC
(n  8,626)
No Pre-Procedural NAC
(n  8,626) p Value
0.0001 430 (5.47) 399 (5.46) 0.99
0.0001 54 (0.63) 50 (0.58) 0.69
0.0001 54 (0.63) 70 (0.81) 0.15
ylcysteine (NAC) compared with those not treated with NAC.nts
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N-acet
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102benefits, studies with stronger methodology have been mostly
negative (22). Furthermore, the field has been dominated by
multiple inadequately powered trials, and it took 10 years for
the first adequately powered trial to be completed. The results
of our work are strikingly similar to that of the recently
presented ACT trial, which found little difference in outcome
of patients randomized to NAC compared with placebo.
Although observational data in general cannot supplant
clinical trials, large studies such as ours can be helpful in
complementing randomized trials, particularly when there
are understudied groups of patients where data might be less
adequate. The results of our study combined with those of
the ACT trial suggest that there is no role for NAC for
prophylaxis of CIN in the vast majority of patients and
across a number of high-risk subgroups. Given the prior
widespread use of this agent, a move away from this practice
should translate into a reduction in healthcare resources and
allow practitioners to focus instead on proven prophylactic
strategies. Although often dismissed as a low-cost therapy,
the administration of NAC in approximately 10% of pa-
tients can add significantly to healthcare cost. Even though
the drug itself is inexpensive, the time, effort, and opportu-
nity costs required for setting up systems to identify high-
risk patients and then to dispense it are not inconsequential.
Study limitations. The BMC2-PCI registry is a regional
database with an active focus on multi-centric quality
improvement and might or might not be representative of
the wider population of patients undergoing PCI in the
United States. Nevertheless, the registry is comprehensive in
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Figure 1. Major Adverse Outcomes in Association With NAC Use
Major adverse outcomes among patients treated with N-acetylcysteine (NAC) c
treated with NAC.that it includes almost all PCIs performed in the state ofMichigan. The registry does not track data on the total dose
of NAC administered, and no dose response analysis could
be performed. The study was also subject to unmeasured
residual confounding, despite propensity-matched analyses
that might influence any of the noted associations. Serum
creatinine was not checked in a systematic fashion, and not
all patients had serum creatinine checked within the 48- to
72-h window that corresponds with peak serum creatinine
elevation in patients with CIN. However, in a sensitivity
analysis restricted to patients with longer length of stay, no
benefit of NAC could be discerned. Finally, the term “CIN”
implies that contrast media are solely responsible for all cases of
renal dysfunction occurring in this population, although this is
probably incorrect. We elected to use this term because there is
no widely accepted alternative.
Conclusions
N-acetylcysteine is commonly used for prevention of CIN in
patients undergoing PCI. No clinical benefit was noted in
association with NAC use. The results of our study com-
bined with those of the ACT trial suggest that this practice
should be abandoned.
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